‘This Breakup Saved You Far More Than Moderna Ever Could’: Orman to Woman Dumped After 180% Spike
A woman with nearly $2 million saved sold her biotech shares when her boyfriend pressured her, watched the stock explode the next day, and then got dumped for it. Suze Orman had something to say about who actually came out…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Suze Orman closed a caller segment on the August 27 episode of her Women & Money podcast with a line aimed straight at a woman who had just been dumped: “Someday you’re going to realize that this breakup saved you far more than Moderna ever could have made you.” The caller, a 44-year-old woman with nearly $2 million in savings, had sold her Moderna (NASDAQ:MRNA | MRNA Price Prediction) shares under pressure from a boyfriend who wanted her to go all in. The day after she sold, the stock exploded. He broke up with her for “failing” him.
Then the stock kept moving. That is where the story actually ends, and where the financial lesson lives.
What the One-Day Pop Actually Looked Like
Moderna closed at $174 on August 19, 2026, up from $63 the prior session, a roughly 177% one-day move. Trading volume surged on cancer-trial news, and anyone who bought at that close was buying the loudest, most crowded print of the year.
The window in which selling early looked catastrophic has already narrowed. Moderna traded as low as $129 on August 20, roughly 27% below the $177 intraday high set on August 19. By August 26 the stock was back at $150, down 14% from the surge close, with a 6% drop on August 26 alone. CNBC’s post-market wrap that day led with hotter-than-expected inflation and Moderna falling.
Why Selling a Volatile Biotech After a Rally Was the Right Call
Orman was right, and the stock proved her right within a week. Concentration risk is the mechanic here, and it does not disappear when the stock is going up. It gets worse. A single-name biotech that moves 177% in one session on trial data can round-trip a meaningful chunk of that move on the next headline.
Consider the alternate universe where she bought at the top. Nearly $2 million deployed at the August 19 close of $174 would be worth roughly $1.72 million by August 26 at $150, a paper loss of about $284,000 in five trading days. The intraday washout to $129 would have shown a temporary drawdown far larger than that.
She kept her roughly $2 million in retirement accounts, pension, and home equity intact. She dodged a single-name volatility bomb that was already leaking.
Position Size Decides Everything
The factor that flips this story is how much of your investable money sits in one ticker. Orman’s rule from the same segment: “If you want to speculate in individual stocks, you are never, ever, ever use more than 5% of your investable money. And only money you could lose without changing your life.”
Apply that to the caller. Five percent of $2 million is $100,000. A 177% one-day pop on that slice would have added roughly $177,000 of paper gain, with the subsequent pullback giving back a portion of it. Life-changing in either direction? No. Survivable? Yes. Now run it at 100% of her net worth, which is what her boyfriend wanted. Against that backdrop, the 61% loss over five years is what happens to concentrated holders when the story changes. (Fencing off speculation with real sizing rules is the whole point of our free playbook on the 5% approach, here.)
Moderna is still an unprofitable biotech burning cash, with FY 2025 revenue of $1.94 billion, down 40% year over year, and 2026 guidance calling for year-end cash of $4.7 billion to $5.2 billion, down from $8.1 billion. Position size is what separates a fun speculation from a retirement-ending mistake.
What to Do With This
- Write down every individual stock you own and calculate what percent of your investable net worth each one represents. Anything above 5% in a speculative single name is where Orman would draw the line.
- For money earmarked for a home purchase or emergency fund, keep it in a money market account, not a biotech. Orman was explicit on this point with the caller.
- Before selling after a rally, ask what a 27% same-week drawdown would do to your plan. Moderna gave holders exactly that test on August 20.
- Never let a partner, a broker, or a podcast host tell you to concentrate money you cannot afford to lose. Orman’s own line to the caller: “You don’t need to become more comfortable taking more risk. You need to become comfortable trusting yourself.”
The caller’s “mistake” got repriced by the market in five sessions. Selling a volatile single stock after a run is rarely the disaster it feels like in the moment. Owning too much of one is.
Contact [email protected] for any questions or corrections.
